Abstract
GLP-1, GIP and Amylin are often mixed up in the same narrative ("everything is incretin"), but they are different axes with different physiological targets - and this changes how you interpret results, risks and limits of proof. This article creates a (high-level) class map and provides a language framework YMYL-safewhat is legitimate to say on the basis of studies and what is overclaim (and why). For operational navigation, cross-reference this reading with the Peptide Database, the Lab Tools and Tactical Lexicon.
Operational Note (S157):
This content is educational and is not medical advice. If you are evaluating evidence on compounds/metabolics, always use conditional language ("associated", "observed", "in trials...") and separate effects of mechanisms. For quality and document validation, it uses the COA Auditor.
This content is educational and is not medical advice. If you are evaluating evidence on compounds/metabolics, always use conditional language ("associated", "observed", "in trials...") and separate effects of mechanisms. For quality and document validation, it uses the COA Auditor.
1) Why "class map" matters
When one reads "GLP-1/GIP/Amilina" as if it were a single block, one loses the ability to:
- Interpreting endpoint vs narrative: weight loss, A1c, satiety, adverse events and adherence don't prove the same thing.
- Separate mechanism (plausibility) from evidence (demonstration): a coherent mechanism does not guarantee net benefit or security.
- Avoid dangerous language: "Cure", "guarantee", "safe", "risk-free", "better for everyone" - all these are signs of low quality.
2) The map - GLP-1 vs GIP vs Amylin (operational view)
| Axle / Class | What tends to modulate | Which does NOT confirm itself | Where to validate in the S157 ecosystem |
|---|---|---|---|
| GLP-1 (GLP-1R agonism) |
Satiety / intake, gastric emptying, glycaemic control (context-dependent), GI signs (tolerability). | It doesn't prove "accelerated metabolism" or "direct fat burning". It does not prove the absence of risk. |
Database (profiles), Journal (critical reading), Lab Tools (metric/PK). |
| GIP (GIPR agonism) | Additional incretin signal; in combination can alter satiety, glycaemia and tolerability profiles. | It doesn't automatically mean "better than GLP-1" in all profiles; it depends on the design, dose and population. |
Lexicon, Database (classes), Journal (comparison of tests). |
| Amilina (amylin/calcitonin analogues / agonism, according to compound) | Signals of "physical" satiety and modulation of intake; in some cases proposed as a complement to GLP-1. | It does not prove "superior safety" or replace risk validation; it does not prove results outside the studied protocol. | Cagrilintide (profile), Lexicon. |
3) "YMYL-safe": safe vs. dangerous phrases
| Avoid (weak signal) | Prefer (S157-safe) | Why |
|---|---|---|
| "This is safe / risk-free." | "In trials, X and Y have been observed; risk and tolerability depend on population, dose and duration." | Security is always conditional and context-dependent. |
| "GIP is better than GLP-1." | "In certain designs, GLP-1+GIP combinations showed different profiles; comparing requires equivalent endpoints." | Indirect comparisons create overclaim. |
| "Amylin melts fat." | "The amylin axis is associated with satiety/ingestion; net effects on body composition depend on multiple factors." | Avoid simplistic mechanism = promise. |
| "Weight loss proves mechanism." | "Weight loss is an outcome; the mechanism requires triangulation (PK/PD, markers, design and plausibility)." | Endpoint is not a causal explanation. |
4) How to read evidence without falling for "scientific marketing"
Use this mental sequence:
- Population: who was studied (obesity? T2D? comorbidities?)
- Design and duration: long enough to see plateau/tolerability?
- Primary endpoint: what was the real target of the study (weight, A1c, events, tolerance)?
- Magnitude vs variability: averages hide dispersion; look for subgroups and dropouts.
- Comparability: Comparing compounds requires comparable doses and contexts (otherwise it's noise).
Shortcut S157:
If your aim is "not to get the interpretation wrong", always cross three layers:
(1) test endpoint + (2) mechanistic plausibility + (3) risk/document quality.
For layer (3), use COA Auditor and Information Use Policy.
If your aim is "not to get the interpretation wrong", always cross three layers:
(1) test endpoint + (2) mechanistic plausibility + (3) risk/document quality.
For layer (3), use COA Auditor and Information Use Policy.
5) Key Terms (shortcuts to the Lexicon)
- GLP-1 - incretin axis and satiety
- GIP - second incretin
- Amilina - physical satiety / intake
- HOMA-IR - insulin resistance metric
- Gastric emptying - mechanism often cited in GLP-1
- Half-life - frequency/exposure reading (high-level)
6) Related Database Profiles (internal shortcuts)
If you want to see how the "class map" appears in specific profiles, open these sheets:
7) Next steps (S157)
- Do you want reading accuracy? Use the Journal for "test comparison" articles and methodologies (HPLC/LC-MS, ISO 17025, chain of custody).
- Do you want to operationalise metrics? Open the Lab Tools and maintains consistent conversions/scaling (e.g: U-100 Calculator to avoid unit errors).
- Want to reduce document risk? Audits reports and batches with COA Auditor.
References
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
- Lau DCW, et al. Efficacy and safety of once-weekly cagrilintide for weight management in adults with overweight or obesity: a randomised, double-blind, placebo-controlled phase 2 trial. (manuscript/academic report made available by institutional repository).
For educational and research purposes only. This article is for documentation, analysis and harm-reduction context. It is not medical advice and does not provide dosing instructions.
EN 
PT 
FR 
ES 
DE 
IT 
PL